2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Breast Neoplasms
576
Carcinoma, Non-Small-Cell Lung
490
Ovarian Neoplasms
328
Lung Neoplasms
208
Fallopian Tube Neoplasms
153
Neoplasms
152
Stomach Neoplasms
128
Esophageal Neoplasms
127
Triple Negative Breast Neoplasms
125
Neoplasm Metastasis
120
Carcinoma, Ovarian Epithelial
115
Squamous Cell Carcinoma of Head and Neck
96
Endometrial Neoplasms
95
Uterine Cervical Neoplasms
80
Head and Neck Neoplasms
78
Esophageal Squamous Cell Carcinoma
76
Adenocarcinoma of Lung
49
Recurrence
48
Parkinson Disease 4, Autosomal Dominant Lewy Body
45
Melanoma
42
Carcinoma
42
Urinary Bladder Neoplasms
41
Adenocarcinoma Of Esophagus
36
Small Cell Lung Carcinoma
34
Carcinoma, Squamous Cell
34
Prostatic Neoplasms
32
Pancreatic Neoplasms
30
Breast Neoplasms, Male
28
Unspecified Adult Solid Tumor, Protocol Specific
27
Adenocarcinoma, Bronchiolo-Alveolar
26
Interventions
veliparib
1
vandetanib
1
pralsetinib
1
osimertinib
1
cemiplimab
1
alectinib
1
Vascular Endothelial Growth Factor A
1
Temozolomide
1
Sorafenib
1
Paclitaxel
1
Liquid Biopsy
1
GSK3352589
1
Docetaxel
1
Crizotinib
1
Carboplatin
1
Capecitabine
1
Antibodies, Bispecific
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Endocrine Neoplasia Type 2a
×
Paclitaxel
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled